A single infusion reversed new-onset type 1 diabetes (T1D) in more than half of treated mice by strengthening regulatory T cells and driving autoreactive CD8+ T cells into a less destructive state.
|Videos|May 27, 2020
The Value of the Pharmacist with Elizabeth Skoy and Amy Werremeyer
Elizabeth Skoy, PharmD, and Amy Werremeyer, PharmD, BCPP, associate professors at the North Dakota State University School of Pharmacy, discuss what they feel is the value of the pharmacist.
Advertisement
Elizabeth Skoy, PharmD, and Amy Werremeyer, PharmD, BCPP, associate professors at the North Dakota State University School of Pharmacy, explain to Pharmacy Times® how the value of the pharmacist is to be an expert on medication and to be an accessible health care provider to patients while serving as an integral member of the health care team.
Advertisement
Related to this article
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
In a Pharmacy Times interview, study coauthor William J. Peppard, PharmD, discusses the association between suzetrigine and fewer opioid refills after knee replacement, the limits of the evidence, and the access barriers pharmacists can help patients navigate.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Novo's topline phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Marissa Reigelman of US Pharmacopeia explains how single-country dependence on key starting materials, combined with low prices, has kept 5 critical injectable drugs in shortage for more than a decade.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ramantamig's 93.6% ORR and Outpatient CRS Control
2
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
5